Â鶹ŮÓÅ

In April, the co-CEOs of Amylyx Pharmaceuticals fulfilled a promise they made years earlier to people with the deadly disease ALS. Justin Klee and Josh Cohen, who started Amylyx while they were students at Brown University, announced that the company would voluntarily stop selling an ALS drug that had brought in $380 million in 2023. (Hamilton, 5/15)

Swiss drugmaker Roche on Wednesday said the US Food and Drug Administration (FDA) has approved its human papillomavirus (HPV) self-testing kit. (5/15)

Eisai (4523.T) and partner Biogen (BIIB.O) said on Tuesday that the Japanese drugmaker has begun submitting data on a rolling basis to the US health regulator for a marketing application of a subcutaneous form of their Alzheimer's disease drug Leqembi. The companies are seeking the Food and Drug Administration's (FDA) approval of a weekly dose of Leqembi to be given as an under-the-skin injection. (5/15)

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk (NOVOb.CO), said on Wednesday it would buy a controlling stake of about 60% in Single Use Support, an Austria-based life science tools company. It declined to give a precise value for the deal but a spokesperson said it would be a "high triple-digit million euros" amount. Single Use Support's two founders will each retain 10% and U.S. life sciences firm Danaher (DHR.N) will retain 20%. (Fick, 5/15)

Germany’s Merck KGaA confirmed and detailed its guidance for 2024 after it reported lower sales and earnings for the first quarter, hit by inventory reductions at its life-science segment. The life-sciences and electronics company said Wednesday that it expects full-year organic sales growth to range from 1% to 5% at the net sales level and to range from 1% to 7% in earnings before interest, taxes, depreciation, amortization and one-time items, the company’s preferred profitability metric. (Calatayud, 5/15)